Truist raised the firm’s price target on American Healthcare REIT to $17 from $16 and keeps a Buy rating on the shares. The company’s potential growth profile is strong relative to the stock’s valuation, and American Healthcare could benefit from acquiring the rest of Trilogy and improving dividend coverage next year, the analyst tells investors in a research note. Truist adds that in the near term, the company is balancing slightly above-target financial leverage with attractive investment opportunities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- Skilled nursing facilities’ outlook likely improved by Chevron ruling, says RBC
- American Healthcare REIT Announces Second-Quarter Distribution
- American Healthcare REIT Declares Second Quarter 2024 Distribution
- American Healthcare REIT Unveils New Investor Presentation
- American Healthcare REIT Unveils Q1 Supplemental Data Insights